Cell Therapy Group, Cancer Research UK Department of Medical Oncology, Paterson Institute for Cancer Research, Manchester, UK.
J Immunol. 2010 Jun 15;184(12):6938-49. doi: 10.4049/jimmunol.0901766. Epub 2010 May 17.
Chimeric Ag receptors (CARs) expressed in T cells permit the redirected lysis of tumor cells in an MHC-unrestricted manner. In the Jurkat T cell model system, expression of a carcinoembryonic Ag-specific CD3zeta CAR (MFEzeta) resulted in an increased sensitivity of the transduced Jurkat cell to generate cytokines when stimulated through the endogenous TCR complex. This effect was driven through two key characteristics of the MFEzeta CAR: 1) receptor dimerization and 2) the interaction of the CAR with the endogenous TCR complex. Mutations of the CAR transmembrane domain that abrogated these interactions resulted in a reduced functional capacity of the MFEzeta CAR to respond to carcinoembryonic Ag protein Ag. Taken together, these results indicate that CARs containing the CD3zeta transmembrane domain can form a complex with the endogenous TCR that may be beneficial for optimal T cell activation. This observation has potential implications for the future design of CARs for cancer therapy.
嵌合抗原受体 (CAR) 在 T 细胞中的表达以 MHC 非限制性方式允许肿瘤细胞的重定向裂解。在 Jurkat T 细胞模型系统中,表达癌胚抗原特异性 CD3zeta CAR(MFEzeta)可使转导的 Jurkat 细胞在通过内源性 TCR 复合物刺激时增加产生细胞因子的敏感性。这种效应是通过 MFEzeta CAR 的两个关键特征驱动的:1)受体二聚化和 2)CAR 与内源性 TCR 复合物的相互作用。破坏这些相互作用的 CAR 跨膜结构域突变导致 MFEzeta CAR 对癌胚抗原蛋白 Ag 的反应能力降低。总之,这些结果表明含有 CD3zeta 跨膜结构域的 CAR 可以与内源性 TCR 形成复合物,这可能有利于最佳 T 细胞激活。这一观察结果对未来癌症治疗用 CAR 的设计具有潜在意义。